In an interview with Pharmacy Times, Robin Tumlinson, PharmD, BCOP, clinical pharmacist specialist in genitourinary oncology at Vanderbilt University Medical Center, discussed recent developments reshaping bladder cancer treatment across disease stages.
As centanafadine awaits DEA scheduling, Megan Maroney, PharmD, BCPP, FAAPP, and Danielle Stutzman, PharmD, BCPP, unpack what its modest efficacy data, favorable interaction profile, and pediatric dosing considerations mean for real-world ADHD prescribing.
Katelyn O'Brien, PharmD, emphasizes sick-day management and preprocedure holds to lower euglycemic DKA risk with sodium-glucose cotransporter 2 (SGLT2) inhibitors.
With a dual glucose-ketone monitor now available, pharmacists must interpret the data and give patients a clear DKA action plan, Goldman says.
Kelsey Norman, PharmD, says addressing provider inertia and asking about adherence at every visit are central to proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor success.
Updated guidelines call for earlier primary aldosteronism screening in stage 2 hypertension, opening a clear role for pharmacists, says Anthony Ishak.
In an interview with Pharmacy Times, Carole R. Berini, PhD, research scientist at Ontada, and Saamir Pasha, MPH, senior biostatistician at Ontada, discussed how validated proxies for missing Eastern Cooperative Oncology Group (ECOG) performance status could strengthen real-world oncology evidence.
In an interview with Pharmacy Times, Carole R. Berini, PhD, research scientist at Ontada, and Saamir Pasha, MPH, senior biostatistician at Ontada, discussed how artificial intelligence and routinely collected clinical data could help address missing Eastern Cooperative Oncology Group (ECOG) performance status in real-world oncology research.
Vicki Saengkheune, PharmD; and Bola Olagunju, PharmD, describe a collaborative clinic where pharmacists titrate therapy, provide counseling, and remove access barriers.
Jackie Burke, PharmD, has advice for strengthening collaborative drug therapy management (CDTM) in a year: ask leaders what they need, then pilot one focused, trackable, reportable workflow.
Jackie Burke, PharmD, says the widest collaborative drug therapy management (CDTM) gap is operational—implementing workflows and showing outcomes, not proving pharmacists' clinical expertise.
The strongest antiobesity medication candidates are chosen by overall health and comorbidities like heart failure, CKD, and sleep apnea, not weight alone.
Katelyn O'Brien, PharmD, says a shared view of cardio-kidney-metabolic syndrome lets pharmacists unify care across endocrinology, cardiology, and nephrology.
Kelsey Norman, PharmD, says pharmacists' longer visits and collaborative practice agreements make them well positioned to get patients to low-density lipoprotein (LDL) goals.
Anthony Ishak, PharmD, explains how the PREVENT risk estimator helps pharmacists calibrate dose intensity and move stage 2 patients to combination therapy.
Led by the moderator, the panelists/expert pharmacists examined common specialty pharmacy and insurance barriers facing patients starting tyrosine kinase inhibitor therapy, sharing proactive strategies such as pre-identifying patient assistance and quick-start programs, securing copay assistance and grant funding, and writing data-driven appeal letters to support payer approvals.
Led by the moderator, the panelists discussed how pharmacists integrate the Total Symptom Score into clinical workflows to track symptom burden over time and distinguish drug-related adverse effects, such as fatigue and cognitive changes, from disease-related symptoms.
The Cleveland Clinic team's real-world findings presented at ESC 2026 are hypothesis-generating and need prospective confirmation but point to a low threshold for OSA screening.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed the need for more meaningful end points in sickle cell pain trials, future research targeting acute chest syndrome, and how pharmacists can improve the collection of opioid-use data.
Publication, conference dissemination, and guideline inclusion are needed for uptake, which has historically been poor for chronic kidney disease (CKD) outcome sets.
Milind Desai, MD, MBA, explains the domino effect linking obesity, obstructive sleep apnea, and hypertrophic cardiomyopathy—and why treating obesity may break the chain.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed how treatment timing and patient heterogeneity may inform the design of future sickle cell pain trials.
A minimum agreed set of outcomes could let pharmacists compare chronic kidney disease (CKD) interventions head-to-head and cut the heterogeneity that has long muddied trials.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial and a pediatric emergency medicine physician at Children’s Healthcare of Atlanta, discussed how patient history and institutional pain-management practices may influence time to crisis resolution and how care teams, including pharmacists, can help standardize treatment.
The panelists examined dosing considerations for avapritinib, starting at 25 mg with titration to 50 mg in indolent systemic mastocytosis (SM) compared with 200 mg in advanced disease, as well as midostaurin's 100 mg twice-daily dosing in advanced SM, emphasizing patient counseling that dose adjustments reflect tolerability rather than treatment failure.
Led by the moderator, the expert pharmacists examined treatment options for advanced systemic mastocytosis (SM), including higher-dose avapritinib, midostaurin for patients without or with unknown KIT mutation status, and cytoreductive agents such as cladribine and interferon for those not responding to or tolerating targeted therapy.
A clinical pharmacy specialist at UPMC Health Plan discusses how pharmacists help select disease-modifying therapies, address adherence barriers, and coordinate whole-person care for those with MS.
In an interview with Pharmacy Times, Claudia R. Morris, MD, lead investigator and author of the phase 3 STArT trial, discusses why intravenous arginine did not shorten time to crisis resolution and how institutional variation, pain heterogeneity, shorter hospital stays, and treatment timing may have influenced the findings.
Glucagon-like peptide-1 (GLP-1) and GIP/GLP-1 agents are just the start: amylin- and glucagon-based mono-, dual-, and tri-therapies are on the horizon.
Pharmacists’ medication expertise can mitigate GI adverse effects and improve outcomes for patients beginning obesity pharmacotherapy
